MindMaze Therapeutics Holding SA (SIX: MMTX) announced the results of its Annual General Meeting held on June 25, 2026, revealing that shareholders approved all proposals submitted by the Board of Directors except for the proposed increase in conditional share capital, which failed to obtain the required qualified majority.
Shareholders re-elected Walid Hanna, Olaf Blanke, and Martin Reiss to the Board of Directors and elected Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members of the Board of Directors. The re-election of Walid Hanna as Chairman of the Board was also approved.
Additional approvals included the 2025 Annual Report and financial statements, the appropriation of available earnings, the discharge of the members of the Board of Directors and the Executive Committee, elections to the Nomination and Compensation Committee, the re-election of the Independent Proxy and the statutory auditor, compensation proposals for the Board of Directors and Executive Committee, and the consultative vote on the 2025 Compensation Report.
The rejection of the conditional share capital increase is significant as it limits the company's ability to issue new shares quickly for potential acquisitions or fundraising. This could impact future growth strategies. Detailed voting results are expected to be published on the company's website later today, as indicated in the AGM Invitation.
MindMaze Therapeutics, a global leader in scalable precision neurotherapeutics, focuses on integrating advanced software, proprietary sensors, and AI-driven data analytics to provide a continuum of care for patients with neurological disorders. Its FDA-cleared and CE-marked products address stroke, Parkinson's disease, and other conditions. The company's stock is traded on the SIX Swiss Exchange under the ticker MMTX. For more information, visit www.mindmazetherapeutics.com.
